Auspex Pharmaceuticals
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $3.0m | Debt | |
N/A | $2.0m | Debt | |
N/A | $2.0m | Debt | |
$12.0m | Series C | ||
N/A | $3.0m | Debt | |
$25.0m | Series D | ||
N/A | $3.0m | Series D | |
$15.0m | Debt | ||
$20.0m | Series E | ||
$3.5b Valuation: $3.5b | Acquisition | ||
Total Funding | €54.5m |
Recent News about Auspex Pharmaceuticals
EditAuspex Pharmaceuticals, a subsidiary of Teva Pharmaceuticals, is dedicated to developing and producing high-quality generic and specialty medicines aimed at improving patient health globally. Operating in the pharmaceutical industry, Auspex serves a diverse range of clients including healthcare providers, pharmacies, and patients across six continents. The company’s business model revolves around the development, production, and distribution of both generic and specialty biopharmaceutical treatments. Revenue is generated through the sale of these medicines, which are designed to be both accessible and effective. Auspex invests heavily in research and development to innovate and expand its product offerings, ensuring they meet the highest standards of quality and efficacy. The company is committed to ethical business practices and strives to make a positive impact on global health.
Keywords: generic medicines, specialty treatments, biopharmaceuticals, healthcare, global distribution, research and development, patient health, ethical practices, pharmaceutical industry, innovation.